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ABSTRACT 
 
Estrogen receptor alpha (ERα) is a ligand activated transcription factor that 
controls key cellular pathways via protein−protein interactions involving multiple 
components of transcriptional coregulator and signal transduction complexes. 
Natural and synthetic ERα ligands are classified as agonists (17β-estradiol/E2), 
selective estrogen receptor modulators (SERMs: Tamoxifen/Tam and Raloxifene/ 
Ral), and pure antagonists (ICI 182,780-Fulvestrant/ ICI), according to the response 
they elicit in hormone responsive cells. Crystallographic analyses reveal ligand 
dependent ERα conformations, characterized by specific surface docking sites for 
functional protein−protein interactions, whose identification is needed to understand 
antiestrogen effects on estrogen target tissues, in particular breast cancer (BC). 
Tandem affinity purification (TAP) coupled to mass spectrometry was applied here 
to map nuclear ERα interactomes dependent upon different classes of ligands in 
hormone-responsive BC cells. Comparative analyses of agonist (E2)- vs antagonist 
(Tam, Ral or ICI)-bound ERα interacting proteins reveal significant differences 
among ER ligands that relate with their biological activity, identifying novel 
functional partners of antiestrogen−ERα complexes in human BC cell nuclei. In 
particular, the E2-dependent nuclear ERα interactome is different and more complex 
than those elicited by Tam, Ral, or ICI, which, in turn, are significantly divergent 
from each other, a result that provides clues to explain the pharmacological 
specificities of these compounds. 
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1. BACKGROUND 
1.1 Breast cancer: statistics and risk factors  
Breast cancer (BC) is the most common cancer diagnosed in women 
worldwide [1]. As a disease that will personally affect the health of one in the 
ten women in the western world [2], BC poses a significant clinical problem 
and is a major public health issue, in the European Union a woman is 
diagnosed with BC every 2 minutes [3]. It was estimated that, in 2008, 
332,800 diagnoses of BC were made in the EU, with death occurring in 27% 
of those diagnosed (89,800 deaths) [3].  
Almost all BCs originate in the glandular epithelium lining the ducts 
and ductules of the breast. A higher incidence of ductal carcinoma in situ 
(DCIS), which are non-invasive tumors, has been reported in the last 20 
years, which is partly due to increased availability of BC screening. 
However, the majority of primary BCs have breached the epithelium and 
invaded into the surrounding stroma by the time of diagnosis (invasive 
carcinoma). Approximately 25% of all BC diagnoses in the United States are 
represented by DCIS [4] DCIS is a non-invasive condition; however it is 
characterized by malignant cells that proliferate into a mass in the breast, and 
it has been reported by various researchers that between 50% and almost 
100% of cases will progress to an invasive phenotype if left untreated [5].  
Hormones have long been implicated in the initiation and progression 
of several cancers, notably of the breast, endometrium and ovary in women, 
and of the prostate, and sometimes breast, in men [6]. The female hormone 
estrogen is a driving factors in BC [7]. Prolongated exposure to estrogen 
through usage of the contraceptive pill or postmenopausal hormone 
replacement therapy [8] are associated with greater incidence of BC. Early 
onset of menstruation or late menopause, both of which prolong the amount 
of time females are exposed to reproductive hormones, are also associated 
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with increased BC risk [9]. BC risk is reduced in women who are of a longer 
age at first pregnancy [10], while breast feeding is also associated with a 
protective effect against the development of BC [11]. This is thought to be 
due to the higher level of differentiation of breast tissue that occurs during 
pregnancy and lactation [12]. Breast tissue that is less differentiated tends to 
comprise a higher proportion of epithelial cells, which are more susceptible 
than other cell types to undergo neoplastic transformation [13] i.e. in women 
who have never been pregnant (nulliparous), or who are older when they 
experience their first full-term pregnancy [12]. There are a number of other 
risk factors to be taken into consideration, such as age at diagnosis, genetic 
mutation, previous BC, race, previous premalignant tumor biopsy, prior 
radiation treatment in the chest area, hormone replacement therapy, obesity, 
poor diet, failing to exercise, fail to breast feed and excessive alcohol intake 
[14]. 
 
1.2 Estrogens  
Estrogens are steroid hormones that are synthesized from cholesterol. 
The most biologically potent and dominant estrogen in humans is 17β-
estradiol (E2), but lower levels of the estrogens estrone (E1) and estriol are 
also present. Estrone is the most abundant estrogen in postmenopausal 
women. In premenopausal women, most of the estrogens are produced in the 
ovary, while in men and postmenopausal women it is produced by 
aromatization and androgens in peripheral tissue. Ovarian production of 
estrogens ceases at menopause, but the hormone is in continual supply at 
other sites postmenopausally, including in the breast, bones, the brain and the 
heart [15]. Tissues that have been reported to synthesize estrogen includes 
muscle, fat, liver and brain [16-19]. The great mass of muscle and fat could 
thereby be expected to be the main contributor to total peripheral estrogen 
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formation. Although aromatase activity and level of expression are low in 
skeletal muscle, such small activity can be compensated for by the bulk of the 
tissue in the body [20]. When estrogens are released into the circulation most 
of it is bound to plasma proteins and transported to target tissue. The steroid 
hormones are lipophilic and have a low molecular weight that enables them 
to enter the target cell by passive diffusion. Estrogens have a broad range of 
target tissues in the human body [21]. For example, estrogens are required for 
female sexual maturation and affects growth, differentiation and function of 
the female reproductive system. In addition, estrogens have important 
physiological effects on the growth, differentiation and function of hormone 
dependent tissues, including breast epithelium, uterus, vagina and ovaries. 
Moreover, estrogens preserve bone mineral density and reduce the risk for 
osteoporosis, protect the cardiovascular system by reducing cholesterol 
levels, and modulate cognitive functions and behavior. In skeleton, estrogens 
prevent bone resorption and estrogen replacement therapy are known to 
reduce osteoporosis in postmenopausal women [22]. In the nervous system 
estrogen has a numerous of different effects such as beneficial for learning 
and memory as well as controlling the hypothalamic-pituitary-gonadal axis 
[23, 24]. In the cardiovascular system estrogen exerts protective effects by 
influencing the vascular function with effects on vascular tone and blood 
flow and subsequently arterial blood pressure [25]. 
 
1.3 Estrogen receptors 
In the early sixties the presence of an estrogen binding receptor was 
first reported by Jensen and Jacobsen [26]. This was isolated and cloned in 
the middle of the eighties by Green et al. (1986) and was for a long time 
believed to be the only existing estrogen receptor (ER) [27]. Then in 1996 an 
additional ER was discovered [28]. This new ER was named ERβ and 
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consequently the first ER was renamed ERα. The ERs belong to the nuclear 
receptor super family and share a common structure including five 
distinguishable domains. They are named A/B, C, D, E and F domains 
(Figure 1.1). The N-terminal A/B domain contains a transactivation function 
that activates transcription of target genes. This domain varies the most 
between ERα and ERβ. The C domain, the DNA-binding domain, is involved 
in specific DNA binding and receptor dimerization. This domain is highly 
similar between ERα and ERβ, which indicates that the target genes are the 
same for the two receptors. They share sequence homology within DNA 
binding domain and hormone recognition region, but have different 
transcriptional activation properties, suggesting that they each interact with 
unique sets of nuclear factors and play different roles in the regulation of 
gene expression [29- 31]. The D domain works as a flexible hinge between 
the DNA-binding domain and the E domain. The E domain is referred to as 
the ligand-binding domain. It is important for ligand binding, receptor 
dimerization and transcriptional activation. The function of the F domain is 
still poorly understood. There are two activation function sites in the ER, AF-
1 and AF-2. The AF-1 is located in the N-terminal and AF-2 within the 
ligand binding domain of the receptor and induces ligand-dependent 
activation of transcription. They are believed to function by binding co-
activators and bringing them to the promoter of the target gene. It can 
function autonomously and in the absence of estrogen. AF-1 is not well 
understood but seems to be weaker in ERβ than the AF-1 of ERα. To give 
full transcriptional response of an ER agonist, a synergism between the 
weaker AF-1 and the stronger hormone inducible AF-2 is required [32]. 
Several different spliced forms of ER have been reported, whether all are 
translated to protein and have any biological function is not established. Even 
though ERα and ERβ are highly homologous their alternative splicing pattern 
differs. Two splice variants of ERα have been shown to inhibit the wild-type 
receptor and might act as regulators of gene transcription [33].  
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Figure 1.1 The structural domains are labelled A–F with the amino acid numbers 
indicated below. Relative positions of some of the known functional domains are 
represented by solid bars. The percentage amino acid homologies between wild-type 
estrogen receptor-α (ERα) and ERβ are also shown. The amino-terminal A/B regions 
contain a transactivation domain (AF-1) with ligand-independent function and a co-
regulatory domain that is responsible for the recruitment of co-activators and co-repressors. 
The C region corresponds to the DNA-binding domain (DBD), which is required for 
binding to specific estrogen response elements (EREs) in the proximal promoter region or 
at distal regulatory elements of estrogen-responsive genes. The carboxy-terminal regions E 
and F contain the ligand-binding domain (LBD) and have a ligand-dependent 
transactivation function. This region is also responsible for the binding to co-regulatory and 
chaperone proteins, as well as for receptor dimerization and nuclear translocation. Finally, 
the D region contains several functional domains, including the hinge domain, part of the 
ligand-dependent activating domain and the nuclear localization signal. Human ERα and 
ERβ variant isoforms are presented below the wild-type forms. Most of these variants are 
expressed in malignant tissues and influence cancer biology. ERβ variants are formed from 
alternative splicing of the last coding exon (shown by the striped bars). From: Thomas et al, 
2011 [151]. 
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Also for ERβ different splice variants have been identified. ERβcx has a 
deletion which makes it unable to bind ligand. However, it can heterodimers 
with preferentially ERα and inhibit ERα induced gene transcription. Another 
ERβ splice variant is called ERβ2 and shows impaired E2 binding ability. 
ERβ2 may function as a dominant negative partner of both ERα and ERβ 
with reduced transcriptional activity. The expression of slice variants appears 
to be tissue specific [34]. Steroid receptor expression and proliferation are 
strictly regulated in the normal mammary gland, but not in malignant tumors. 
In normal mammary gland there is a minimum expression of ERα [35, 36]. 
ERα expression increases when normal mammary cells are proliferating such 
as the case of pregnancy and puberty period [37, 39]. However in BC 
increased ERα expression appears to occur early in the premalignant to 
malignant progression, and these tumor cells will continue expressing ERα 
[40]. In fact, it facilitates epithelial mammary cells to turn from a condition 
of hormone dependence to hormone independence. Recent transcriptome 
analyses confirmed observations made over a century ago, that estrogens 
stimulated the development of the disease in at least one out of five patients. 
If, from one side, the expression of ERα is a risk factor for the development 
of BC, from the other side, this expression is associated with responsiveness 
to hormonal treatment and with favorable prognosis [41]. Nevertheless, 
clinical evidence shows that more than 30% of hormone receptor-positive 
mammary tumors are unexpectedly non responsive to endocrine treatment. 
Reasons for therapy failure seem to lie not only in ER dysfunction, but also 
in mutations affecting the intracellular signal pathway of estrogens. In this 
regard characterizing ER networks will help to elucidate molecular 
mechanisms responsible for hormone resistance in breast tumors and will 
allow to detect new molecular markers for a more accurate BC prognosis. 
Although ERβ is widely expressed in both normal and malignant breast 
tissue, it is not thought to be as important as ERα in predicting response to 
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endocrine therapy [42]. Its function, if any, in BC progression, is not well 
understood. Additionally, ER-negative breast tumors are poorly differentiated 
and more aggressive [43]. The difference in ER expression between normal 
(low ER expression) and tumor cells (variable ER expression) raises the 
question as to why ERα is absent both in the normal breast epithelial cells 
and in the worse prognostic breast cancers while ERα is present in the breast 
epithelia cells in luminal like? Should the presence of ERα be our only 
marker or there are other elements to determine the prognosis of the disease. 
There are two possibilities as to why lack of ER is associated with a poor 
prognosis: i) an ER-positive tumor has the ability to lose ER expression and 
in doing so be transformed into a more aggressive ER-negative tumor or ii) 
ER-negative tumors originate from cells without expression of ERα. There 
are active investigations in support of both of these possibilities [44-48]. The 
tissue distribution of ERα and ERβ is in part different. Classical estrogen 
targets are the uterus, mammary gland, placenta, central nervous system, 
cardiovascular system and bone. These tissues have a high ERα content. 
Non-classical target include prostate, testis, ovary, adrenals, pancreas, skin 
and urinary tract [49]. The expression ERα is either low or not measurable in 
these tissues. Besides the classic estrogen tissues, ERβ is also highly 
expressed in many non-classical estrogen target tissues [50]. ERβ has a 
broader tissue distribution than ERα suggesting that the two receptors have 
distinct biological functions. This is evident hen studying the different 
phenotypes of ERα and ERβ knock-out mice (αERKO and βERKO, 
respectively). Both single and double knock-out mice can survive to 
adulthood, albeit with retarded growth. The most striking phenotypes in 
αERKO mice are complete infertility in both sexes. In contrast, male βERKO 
mice are fertile whereas the females are sub fertile; they have fewer litters 
with reduced number of pups [51]. The basal release of endometrium-derived 
NO is decreased in male αERKO [52] and the estrogen mediated production 
 10 
of NO is abolished [53]. βERKO mice developed hypertension in both sexes 
as they age [54], which confirms their role in the cardiovascular system. 
 
1.4 Estrogen receptor signaling  
It was for many years believed that the only mechanism by which 
estrogen affected expression of estrogen-responsive genes was by direct 
binding of the activated ER to specific estrogen response elements (ERE) on 
DNA (Figure 1.2). However, evidence for signaling pathways that deviate 
from this classical model has emerged. Today, it is accepted that ER may 
regulate transcription  
 
 
Figure 1.2 A simplified model of estrogen dependant gene transcription. From: Shi et 
al, 2007 [152]. 
 
from target genes by a number of distinct mechanisms, both in the presence 
and absence of estrogen (Figure 1.3). Activation of ER appears to be a multi-
step process relying on a number of molecular events, including 
dimerization, the actual binding of ligand, phosphorylation, interaction with 
cofactors and DNA binding.  
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Classical ligand-dependent activation of ER. In the absence of ligand, 
ERs are preferentially located to the cell nucleus in a multiprotein complex 
containing heat shock proteins [55]. When estrogens, which can diffuse 
across the plasma and nuclear membranes of cells, bind to the ER a 
conformational change occurs that promotes receptor dimerization. The 
activated ERs bind as homodimers or heterodimers to EREs located in the 
regulatory regions of target gens. The ERE sequence is a 13 base par 
palindromic inverted repeat with the consensus sequence: 5’-
GGTCAnnnTGACC-3’. The binding of ERs to the EREs facilitates the 
assembly of basal transcription factors into a stable pre-initiation complex 
and increases transcription rate for target mRNA synthesis [56]. The 
conformational change of activated ERs also leads to that an interaction 
surface for co-activators is provided. Ligand-dependent activation of 
transcription by ERs is mediated by the interactions of a number of different 
nuclear receptor co-activators.  
Coregulatory proteins. Interactions of the DNA-binding domain of ER 
with promoters of target genes can be further modulated by the presence of 
specific nuclear co-regulator proteins that are recruited to gene promoters, 
where they interact with receptor-ligand complexes (Figure 1.4). When ER is 
in an inactive, unliganded conformation, it is bound to nuclear co-repressors 
(NCoR) such as NCoR1, and silencing mediator of retinoic acid and thyroid 
hormone receptor (SMRT). NCoRs recruit histone deacetylases (HDAC) to 
promote deacetylation of histones, thus maintaining the chromatin in a 
condensed, transcriptionally inactive state [57]. E2-binding to ER induces a 
conformational change in the AF-2 domain of the receptor, facilitating direct 
interaction with co-activator proteins. Histone acetyltransferases (HAT) are 
then recruited, leading to acetylation of histones, unwinding of chromatin and 
activation of transcription [58]. The p160 family of proteins are steroid 
receptor co-activators (SRC) that have the ability to stimulate steroid receptor 
transcriptional activity. 
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Figure 1.3 Model representing the mechanistically distinct molecular pathways used in 
the regulatory actions of ERs. The classical (direct) pathway includes ligand activation and 
a direct DNA binding to estrogen response elements (ERE) before modulation of gene 
regulation. The tethered pathway includes protein-protein interaction with other 
transcription factors after ligand activation, and thereby gene regulation is affected by 
indirect DNA binding. A third mechanism, also called nongenomic with rapid effects, is 
not as well understood as the genomic mechanism but has been observed in many tissues. 
The ligand activates a receptor, possibly associated with the membrane; either it is a 
classical ER, an ER isoform or a distinct receptor  or, alternatively, a signal activates a 
classical ER located in the cytoplasm. After this rather unclear event, signaling cascades are 
initiated via second messengers (SM) that affect ion channels or increase nitric oxide levels 
in the cytoplasm, and this ultimately leads to a rapid physiological response without 
involving gene regulation. The ligand-independent pathway includes activation through 
other signaling pathways, like growth factor signaling. In this case, activated kinases 
phosphorylate ERs and thereby activate them to dimerize, bind DNA, and regulate genes. 
From: Heldring et al, 2007 [153]. 
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Figure 1.4 The role of co-activators and co-repressors in transcriptional repression and 
activation of ER-regulated genes. A: in the absence of ligand, ER is present in cells as a 
monomer, bound to nuclear co-repressors (NCoR) and histone deacetylases (HDAC), 
which maintain chromatin in an inactive state (REPRESSION). B: upon ligand-E2 binding 
ER dimerises and binds to the promoter, releasing bound NCoRs, and favoring association 
with co-activator proteins (NCoA). The formation of this complex at promoter regions of 
ER target genes recruits proteins with histone acetyltransferase (HAT) activity, such as 
CBP/p300, leading to chromatin unwinding and transcriptional activation (ACTIVATION). 
From: Glass et al, 2000 [58]. 
 
This family includes SRC-1 (also known as NCoA1, SRC-2 and SRC-
3). The SRC proteins contain multiple structural and functional domains; the 
receptor interaction domain (RID) in the central region of the protein 
contains several conserved motifs (LLXXL; where L= leucine, X= any 
aminoacid) that allow these co-activators to interact with ligand-bound 
nuclear receptors at promoters of target genes [59, 60]. Two transcriptional 
activation domains (AD) are located in the C-terminal region of SRCs. AD1 
contains multiple LXXLL motifs that allow SRCs to bind to the co-
integrators CREB-binding protein (CBP) and p300, facilitating transcription 
through histone acetyltransferase activity [61]. AD2 binds to a protein called 
co-activator associated arginine methyltrasferase 1 (CARM1), which acts as a 
secondary ER co-activator, to AIB1 [62]. 
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Ligand-independent activation of ER. The ERs can also be activated 
without any estrogen present. Within the AF-1 site of ER there are well-
conserved serine residues, which are target for phosphorylation. Binding of 
growth factors, such as IGF-1 and epidermal growth factor, to its cognate 
receptor results in the intracellular activation of mitogen-activated protein 
kinase (MAPK) signal transduction cascade that influences the transcriptional 
activity of the ERα by phosphorylation of serine residues [63, 64]. Trembley 
et al. showed a similar ligand-independent activation of the ERβ [65]. 
Phosphorylation events have been demonstrated to be the foremost 
mechanism in the ligand-independent activation of ER. Estrogen also induces 
phosphorylation of serine residues, but this appears to be independent of 
MAPK [66]. It is also described that a combined stimulation with growth 
factors and estrogen gives potentiated effect [67]. In bone cells, mechanical 
strain has a similar effect on increasing ERE activity as more prolonged 
exposure to estrogen [68]. It is suggested that strain has its effects on 
increased ERE activity by phosphorylation of the ER using kinase-dependent 
signaling pathways [69]. Strain-induced ER phosphorylation does not require 
the presence of estrogen, but is dependent on extra-cellular regulated kinase 
(ERK), a member of the MAPK family [70]. ER may also be activated by 
cAMP induced signaling [71]. Activation via cAMP signaling pathway 
requires the AF-2 site, in contrast to the MAPK which requires the AF-1 site, 
and appears to be dependent on protein kinase A that is activated by cAMP. 
This represents a pathway distinct from activation via peptide growth factors. 
Non-ERE-dependent activations of ER. In addition to binding to the 
ERE, the activated ERs can interact with other DNA-bound transcription 
factors to regulate the transcription of certain sets of genes. In this 
mechanism, ERs do not themselves bind DNA; instead it is tethered by 
protein-protein interactions to a transcription factor complex that contrasts 
the DNA. AP-1 sites and SP-1 sites are well characterized motifs that could 
mediate estrogen signaling via other bound transcription factors, such as 
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FOS/JUN [72]. The discovery of this mechanism explains how estrogen 
regulates genes in which no consensus ERE has been found. 
Non-genomic signaling. There is evidence that estrogen has non-
genomic effect too, since very rapid effects of estrogen have been observed 
[73]. These effects are too rapid to be accounted for by transcriptional 
activation or repression of target genes, which occurs with a time lag of 
several hours. These effects occur within seconds to minutes after estrogen 
treatment and cannot be blocked by transcription or translational inhibitors. 
Studies have suggested that these effects may be the result of estrogen 
activation of MAPK and ERK signaling [74] or release of intracellular 
calcium [75]. The MAPK pathway is rapidly activated by estrogen in various 
cell types, for example endothelial cells [76]. Some of the protective effects 
of estrogen in the cardiovascular system are mediated by a non-genomic 
mechanism involving rapid activation of eNOS by estrogen through the 
MAPK pathway [77]. The activated eNOS releases NO which promotes 
vasodilatation. eNOS is also regulated on the genomic level by estrogen by 
activating an ERE-sequence in its promoter region [73]. 
 
1.5 Breast cancer treatment: endocrine therapy 
Given the critical importance of ER signaling in BC initiation and 
progression, efforts have been made to block this pathway therapeutically. In 
addition to chemotherapeutic regimens, eligible patients receive endocrine 
therapy. Patients will be categorized into ER-positive group versus ER-
negative group based on the result of immunohistochemistry (IHC) test, 
which is a widely used test for assessing therapeutic biomarkers (such as ER) 
and has become a major part of practical diagnosis for various malignancies 
[78]. The ER-positive patients are eligible for endocrine therapy [79]. 
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Current endocrine therapies are based on synthetic compounds that 
either act as estrogen antagonists (antiestrogens) or block the function of 
aromatases (the enzymes that catalyze the last step of estrogen biosynthesis) 
have been thought. Antiestrogens are designed to antagonize hormone 
induced proliferation and ERα target gene expression in mammary tumor 
cells (Figure 1.6) [80]. Within the antiestrogens it is possible to distinguish 
two major classes of drugs, depending on their functional effects. The 
“Selective Estrogen Receptor Modulators” (SERMs) are separate 
antiestrogens able to act as both receptor agonists and antagonists (mixed 
agonists-antagonists), depending on the cellular and promoter context as well 
as the ER isoform targeted (tissue-specific properties). The “Selective 
Estrogen Receptor Downregulators/Disruptors” (SERDs) are classical pure 
antiestrogens (pure antagonists), capable to completely block the activity of 
E2, to increase ER turnover and to disrupt its nuclear localization with a 
concomitant reduction in the number of detectable ER molecules in the cells 
both in vitro and in vivo. In general, this class of ER ligands plays an 
important role as a second line therapy against advanced BC in patients who 
develop resistance to SERM treatment [81].  
The molecular targets of these anti-hormone therapies are the ERs. All 
ERα ligands bind exclusively to the carboxy-terminal (C-t) ligand-binding 
domain (LBD). The LBD of the ER recognizes a variety of compounds 
diverse in their size, shape, and chemical properties. The ERα activity is 
mediated by at least two separate activation functions (AFs), AF-1 in the 
amino-terminal (N-t), and AF-2 in the LBD. The activity of AF-1 is regulated 
by growth factors acting through MAP-kinase signaling pathway [82], while 
AF-2 activity is responsive to agonist ligands [83]. The binding of agonists 
triggers AF-2 activity, whereas the binding of antagonist does not [84]. 
Several studies suggest that ligands regulate AF-2 activity by directly 
affecting the structure of the LBD. Any ligand-induced conformational 
change involving the repositioning of helix 12, the most C-t helix of the 
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LBD, is essential for AF-2 activity (Figure 1.5). Indeed, from X-ray 
crystallography studies the ligand-dependent orientation of helix 12 has 
emerged as the principal determinant that distinguishes the function of 
estrogens from antiestrogens. In the ER complexes with estrogens, the 
position of helix 12 creates a co-activator binding site, whereas the position 
of helix 12 in ER-antiestrogen complexes blocks co-activator binding. [85, 
86]. Mutational and structural studies highlighted that the helices 3, 5, 6, 11 
and 12 form a hydrophobic pocket which envelops the steroid ligand and 
represents the static region of the AF-2 and a recognition surface, created in 
presence of agonist, for the co-activators linking the ER to the RNA pol II 
transcriptional machinery. [87- 89]. The first antiestrogen introduced in the 
clinical practice is tamoxifen (also referred to in the literature as Nolvadex®), 
that is also known as the SERM prototype. [90, 91].  
 
 
Figure 1.5 Major conformations induced by ER agonists and antagonists. Schematic 
representation of ERs bound to E2 (A), E2/LXXLL NR-box (B), raloxifene (C), genistein 
(D), and ICI (E). The location of AF-2 between H3-H5 and H12 is indicated in A. The 
position of H12 is indicated by a green cylinder. The LXXLL peptide is shown as a purple 
cylinder with leucines in stick form in B. From: Heldring et al, 2007 [153]. 
In 1967 Dr Arthur L. Walpole discovered the compound ICI 46,474 in 
the laboratories of what is now the AstraZeneca pharma company [92], 
formerly Imperial Chemical Industries (ICI) and performed the initial studies 
in rodents. This drug, which later was named tamoxifen, tested on immature 
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rat, showed both estrogen agonist and antagonist effect, while on mouse only 
showed a full estrogen agonist effect. It was found that this compound, while 
functioning as a contraceptive in rats, did not exhibit equivalent activity in 
humans; however, it was initially proposed to act as a post-coital 
contraceptive agent and showed promise as an inducer of ovulation for 
women with challenged fertility. It was discovered latterly that, in humans, 
tamoxifen was modestly active in treating breast cancer, similarly to the high 
doses of estrogens or androgens that were already in clinical use [93]. 
Laboratory research into tamoxifen activity was temporary shelved until later 
in the 1970s, when it was discovered that is metabolic activation to 4-
hidroxytamoxifen increased its binding affinity for ER by approximately 
100-fold [94]. Tamoxifen is a no-steroidal antiestrogen that antagonizes the 
action of estrogen and is effective in both the treatment [95] and prevention 
[96] of ER-positive breast cancer [97, 98]. Although concerns were raised 
regarding the potential antiestrogenic effects on normal tissue, paradoxically 
tamoxifen acts as an estrogen on bone, blood lipids and the endometrium 
[99]. In the adjuvant and prevention settings this may increase the risk for 
endometrial cancer and thrombotic events in women taking tamoxifen, 
although the risk has been perceived to be small in relation to the substantial 
benefit from reduction in BC related events. Indeed, BC incidence was 
observed to be reduced by 48% in an at-risk population [96]. Nevertheless, 
breast epithelial cells and established carcinomas adapt to chronic 
antiestrogens exposure and develop resistance to tamoxifen, which may also 
result from the drugs partial agonistic activity stimulating tumor regrowth. 
[100, 101]. Tamoxifen has been a significant clinical success story for the 
treatment of hormone-responsive breast cancer, with accompanying 
observations that five years of adjuvant therapy in pre-menopausal ER 
positive patients was the optimal duration to improve disease free survival 
(DFS) and overall survival (OS) [102]. 
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Raloxifene (also referred to in the literature as LY 156,758, keoxifene, 
LY 139, 481-HCL, Evista®), a second-generation SERM, was not developed 
as an antiestrogen for breast cancer, and a few data exist on the activity of 
raloxifene in patients with advanced cancer disease [103]. The goal was to 
introduce a new hormone replacement therapy to prevent osteoporosis but 
this drug proved to decrease the incidence of endometrial cancer and BC in 
the general population as a beneficial side effect [104]. Raloxifene is a no-
steroidal antiestrogen produced by altering the triphenylethylene ring 
structure of tamoxifen to get a benzothiophene “fixed ring” structure. It has 
been evaluated in more than 11,000 postmenopausal women and has been 
found to maintain bone density with a decrease in BC incidence, in particular 
ER-positive tumors, in postmenopausal women by 76%, and no increase in 
endometrial thickness. Raloxifene exhibits binding affinity for the ER similar 
to that of tamoxifen but a lower estrogenic activity. It also has a potent 
antiestrogenic activity. Indeed, raloxifene exhibits estrogen-like effects in 
bone cells, preserving the bone mineral density, but not in uterine cells. It can 
rather block the uterotrophic action of both estrogen and tamoxifen. 
Furthermore raloxifene causes a decrease in circulating cholesterol, showing 
a beneficial side-effect in cardiovascular tissue [103]. Overall, raloxifene 
displays the profile of a SERM that could be applied as a potential preventive 
for osteoporosis in postmenopausal women but with the additional benefits of 
preventing BC and coronary heart disease and resulting into a better toxicity 
profile in terms of gynecological problems compared to tamoxifen [105]. At 
present, raloxifene is mainly used in a prophylactic capacity, to prevent the 
onset of BC in particularly high-risk patients [106]. As molecular effects of 
SERM compounds, ER leads to loss of heat shock proteins (HSPs), 
dimerization and phosphorylation of receptors, but with a specific 
conformational shape leading to co-activator action at AF-1 only and not at 
AF-2 site. The most striking feature of the structures of the tamoxifen- and 
raloxifene-liganded ERα LBD’s is that helix 12 directly affects the structure 
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and function of the AF-2 surface in two ways. First, since helix 12 residues 
form an integral part of the AF-2 surface, AF-2 surface is incomplete when 
helix 12 is in the SERM-bound conformation. In particular, the critical 
aminoacids, such as Leu-539, Glu-542, and Met-543 are incorrectly oriented 
for co-activator recognition. The alkylaminoethoxy bulky side chain of the 
tamoxifen and the benzothiophenes “fixed ring” of the raloxifene project out 
of the hydrophobic pocket between helices 3 and 5 [107, 108] and, therefore, 
prevent helix 12 from repositioning and sealing, as a “lid”, the ligand in the 
hydrophobic pocket. Second, residues from the static region of the AF-2 
surface are bound to helix 12 and are prevented from interacting with co-
activators. Indeed the aminoacids, that are critical for the co-activator 
recruitment are now masked [108]. The relative balance in a given cell type 
of co-activator and co-repressor proteins may also determine the given 
response to a particular ligand. Likewise, in the endometrium tamoxifen, but 
not raloxifene, may have estrogenic-like effects due to recruitment of co-
activators to a subset of genes and this aspect may vary in different tissues 
depending on the background level of expression of co-activators (Figure 
1.4) [109]. 
Fulvestrant (also known as ICI 182,780, Faslodex®), a SERD 
prototype, is a steroidal molecule devoid of estrogen-like activity in any body 
tissues. It was designed in order to treat patients with hormone sensitive 
breast tumors, that, after tamoxifen first line therapy, developed SERM 
resistance and showed on the gynecological tract side effects due to the 
SERM agonist activity on ER [110]. The absence in SERDs of agonist 
activity on the ER leads to the overcoming of the drug resistance 
development which limits the effectiveness of long-term tamoxifen therapy. 
 21 
 
 
Figure 1.6 Molecular structures of the 17β-estradiol (E2) , tamoxifen, 4-
hydroxytamoxifen (Tam), raloxifene (Ral), ICI 182,780 (fulvestrant). From: Heldring et al, 
2007 [153]. 
Indeed, clinical studies demonstrated that proliferation of tamoxifen-
resistant BC cell lines is again inhibited by fulvestrant [111, 112]. As far as 
the molecular activity concerns, fulvestrant competitively inhibits the binding 
of estrogen to the ER and binds to ER with an affinity that is about 100 times 
that of tamoxifen [110, 113]. As previously highlighted for SERMs, also for 
fulvestrant the alignment of the C-terminal transactivation helix (H12) over 
the LBD of ER is prevented, because of its long bulky 7a side chain. In 
addition the positioning of the terminal amide portion of the side chain 
precludes H12 from adopting its alternate orientation along the co-activator 
binding shallow groove of AF-2. As a result fulvestrant abolishes association 
between H12 and LBD, affecting the AF-2 functionality. Furthermore, the 
ER abnormal conformation results in loss of receptor dimerization and 
accelerated ubiquitylation and shuttling of the ER to the proteasome for 
degradation [111, 112, 114]. Indeed, a down regulation of the ER protein 
expression, that is, a reduction in the number of detectable ER molecules in 
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the cells both in vitro and in vivo, is observed. The ER rapid degradation 
plays a key role in the molecular basis of full antagonism of fulvestrant, 
because it also causes lack of the AF-1 agonist activity which, instead, is 
effective in SERMs. Fulvestrant shows a full antagonist activity on breast 
and endometrium without affecting bone density and serum lipids, and 
currently has been approved for the treatment of BC which has progressed on 
prior antiestrogen therapy in postmenopausal women. In the wake of 
emerging resistance to tamoxifen it was recognized that removal of E2 from 
the environmental of the tumor might prove to be a more effective method of 
blocking ligand-dependent ER-mediated signaling.  
In this context, a spotlight has appeared on aromatase inhibitors as a 
novel endocrine therapy option in the past decade [57]. Instead of blocking 
binding of E2 to ER, these compounds act by preventing E2 biosynthesis 
catalyzed by the aromatase enzyme in extra gonadal tissue.  
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2. AIMS OF THE STUDY  
Since clinical evidence shows that more than 30% receptor positive 
mammary tumors are unexpectedly non-responsive to endocrine treatments, 
and the reasons for such failure have been suggested to depend on the 
functions of ER and/or the intracellular signaling pathway controlled by 
estrogens, in this regard, dissection of the ER signaling networks in hormone-
responsive BC cells, a useful approach to identify the molecular mechanisms 
of cell responsiveness to estrogen, may provide new insights on resistance of 
breast tumors to endocrine therapies. Interaction proteomics led so far to the 
identification of a large number of E2−ERα interactors in BC cell nuclei, 
including transcriptional coregulators and components of the nuclear actin 
pathway [115-118]. 
The main purpose of this study was to apply this technology to map 
the nuclear interactomes of ERα bound to the antiestrogenic compounds 
commonly used for BC treatment (i.e., ICI, Ral, and Tam), aiming at 
providing new mechanistic information to help explain the pharmacological 
activities of these drugs in BC cells in vitro and in vivo. 
To this purpose, the following specific aims were defined: 
1) isolate and identify the ERα interacting proteins when the receptor is 
bound to several antiestrogen compounds of common clinical use or to the 
endogenous ligand; 
2) compare the compositions of the different ERα interactomes 
(receptosome) in order to identify the specific molecular partners of each 
antiestrogen compound and, in particular, those common to the two SERMs; 
3) investigate the molecular processes and biological functions globally more 
representative for each ligand. 
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3. RESULTS AND DISCUSSION  
3.1 Evaluation of ligand effects on the intracellular localization of wild-
type and TAP-tagged ERα 
The cellular model used in this study was derived from hormone-
responsive human BC MCF-7 cells, naturally expressing ERα and widely 
used to investigate signal transductions by ERs in BC and to test the 
pharmacological effects of ER ligands. MCF-7 cells were stably transfected 
with an expression vector encoding ERα fused at the C-terminus with a TAP 
tag [119, 120] that can act as a “bait” for isolation of native ER containing 
multiprotein complexes by tandem affinity purification (TAP). These cells 
have been used successfully for mapping and functional characterization of 
E2-induced ERα nuclear interactome by TAP [117, 118, 121] As 
antiestrogens have been described to influence in different ways the cellular 
level and/or localization of ERα, the behavior of the exogenous fusion 
protein with respect to the endogenous receptor was assessed upon cell 
treatment with either E2, ICI, Ral, or Tam. In all cases, the nuclear levels of 
TAP-ERα were assessed by Western blotting and compared to those relative 
to endogenous ERα in the same samples or, for E2, in wt MCF-7 cells 
(Figure 3.1). Results, summarized in the histogram, show that the exogenous 
receptor behaves similarly to the endogenous one in all cases, as 
demonstrated by Ambrosino et al. [117]. Interestingly, comparing the results 
obtained for edogenous receptor in E2- treated wt and TAP-ERα cells, the 
former exhibit higher ERα levels, possibly due to inhibition of endogenous 
receptor expression by the exogenous protein [117]. The pure antiestrogen 
ICI disrupts nuclear-cytoplasmic shuttling of both ERα and TAP-ERα, 
possibly by inducing proteasome-dependent ER degradation [122, 123], as 1 
h treatment of the cells with this compound causes a modest increase of 
receptor concentration in the nuclear extracts, when compared to that elicited 
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by E2 (Figure 3.1). On the other hand, the two SERMs (Ral and Tam) induce 
substantial nuclear accumulation of both receptor forms, with Tam being less 
effective than E2, but more than Ral, as described for endogenous ERα in this 
cell type [124]. Kinetic evaluation of nuclear translocation of ER was 
performed after 1, 6, and 12 h of treatment with each of the compounds 
studied by WB analysis of ERα and TAP-ERα both in the nucleus and in the 
cytoplasm, with β-actin and α-tubulin, respectively, used as controls. Results, 
reported in Figure 3.2, show that while E2 and SERMs induce a substantial 
accumulation of both ERs in the nuclear compartment for up to 12 h of 
treatment, ICI effects are not only less pronounced but also dynamic, since 
nuclear ER concentration decreases between 1 and 6 h and then rises again at 
12 h.  
 
 
 
 
 
 
 
 
Figure 3.1 Western blot analysis of ERα and TAP-ERα in MCF-7 nuclear extracts, 
normalized to nuclear β-actin (ACTB) concentration in the same samples, from cells treated 
with E2, ICI, Ral, and Tam (10
–8
 M; 1 h). (C) Wild-type MCF-7 cells, not expressing TAP-
ERα, stimulated with E2, used as negative control. Relative quantitation of TAP-ERα and 
ERα compared to ACTB is shown in the histogram. 
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Figure 3.2 Time-course analysis of ERα and TAP-ERα nuclear traslocation induced 
by E2, ICI, Ral, Tam (10
-8
M) or vehicle alone (V) by Western Blotting. (A) Nuclear 
extracts (TAP-ERα cells to the left and wt cells to the right). The histograms show TAP-
ERα and ERα levels, relative to β-actin (ACTB), in treated vs untreated cells. (B) 
Cytoplasmic extracts (TAP-ERα cells to the left and wt cells to the right). TUBA: α-
Tubulin. 
3.2 Effects of estrogen and antiestrogens on the transcriptome of TAP-ERα 
expressing cells  
ERα exerts its biological effects through several mechanisms, that all 
converge on regulation of target gene expression. As the different ligands 
affect recruitment of co-regulators on ERα, their influence on the ER 
dependent transcriptome in MCF-7 cells was investigated by gene expression 
profiling with oligonucleotide microarrays. To this end, TAP-ERα expressing 
MCF-7 cells were stimulated for 12 h with either E2, ICI, Ral, or Tam, and 
total RNA was extracted, fluorescently labeled, and analyzed on high-density 
oligonucleotide microarrays. This time of stimulation was chosen in order to 
better evaluate early, primary responses to the ligands, with respect to late, 
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secondary events in TAP-ERα cells, as shown by Cicatiello et al. for E2 in wt 
MCF-7 [125] and another hormone-responsive BC cell line [126]. Untreated 
TAP-ERα cells were used as a control. The results obtained are summarized 
in the heatmaps reported in Figure 3.3, where data are reported relative to 
mRNAs that showed a ≥2 fold-change, with respect to the control, in 
response to stimulation with each of the four compounds tested. In each case, 
changes in expression of the same mRNA under all four conditions are also 
reported, side by-side, to highlight similarities and differences in gene 
response to different ER ligands. Results show that gene activation clearly 
prevails over inhibition in response to E2 stimulation, as 2/3 of the transcripts 
show significantly higher levels in treated vs untreated cells, while, on the 
contrary, gene down-regulation events appear predominant following anti- 
estrogen treatment, independently from the nature of the drug used. As 
expected, under these conditions most of the genes regulated by estrogen do 
not respond similarly to antiestrogens. When comparing the overall responses 
of the MCF-7 cell transcriptome to the three antiestrogens tested, the effects 
appear strikingly different. First of all, the total number of genes responding 
to ICI is very low, when compared to the responses elicited by two SERMs, 
in agreement with the low nuclear ER concentration in the presence of this 
ligand and the known effects of ICI in hormone-responsive BC cells [127], 
with ICI regulated genes generally responding similarly also to Tam and Ral. 
Furthermore, Tam-responsive genes are more numerous than ICI-regulated 
ones and show similar regulation by Ral, but not by E2. This is in accordance 
with the observation that these SERMs promote ERα translocation to the 
nucleus and induce very similar conformational changes of the receptor, that 
are different from those promoted by binding of the cognate hormone. The 
effects of Ral on the cell transcriptome, however, are much more evident and, 
in most cases, unique to this drug. Taken together, the results shown in 
Figures 3.1, 3.3, and 3.4 reproduce correctly the known biological effects of 
these drugs in hormone-responsive BC cells, that are here confirmed to be 
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strictly related to the chemical structure of each compound and its ER 
binding properties, to indicate that the experimental model described here is 
suitable to identify functional protein partners of antiestrogen-bound ERα by 
interaction proteomics.  
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Figure 3.3 Interaction genomics of agonist- and antagonist-bound ERα in MCF-7 
cells. Heatmaps summarizing the results of transcriptome analyses of TAP-ERα-expressing 
MCF-7 cells treated (10
–8
 M; 12 h) with E2 (top-left), ICI (midleft), Tam (bottom-left), or 
Ral (right). For each ligand, gene expression fold-changes were calculated with respect to 
the untreated control. 
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3.3 Identification of proteins recruited by ERα in the nucleus of BC cells in 
response to E2, ICI, Ral, or Tam  
In order to identify ERα partner proteins specifically recruited by the 
receptor upon binding of an agonist (E2) or of different antagonist (ICI, Ral, 
Tam) ligands, partially purified ERα protein complexes isolated from native 
MCF-7 cell nuclear extracts were subjected to MS analysis (nanoLC-
MS/MS). As control, wt cells, lacking the TAP-tagged receptor, were subject 
to the same purification−identification protocol and all proteins identified in 
these samples were considered not specific, and, for this reason, when 
present, they were discarded from the lists of specific ERα interactors and not 
considered further, as described by Tarallo et al. [118]. In addition, when 
focusing on SERMs specific ERα complexes, the proteins identified in ICI-
treated samples were subtracted from the number of the Ral and Tam 
interactors and listed as a separate set. Two biological replicates were 
performed, and when the resulting MS data were analyzed separately, a very 
good reproducibility was observed (>60% identified proteins in common 
between the replicas), suggesting reliability of the purification procedure. To 
identify ligand-specific ER-associated nuclear proteins, the MS results from 
the two biological replicates were combined and analyzed together, to obtain 
more robust data sets. Results of this analysis, detailed in the Materials and 
Methods section, are listed in Tables 3.2-3.5 for E2, ICI, Ral, Tam, 
respectively, and are summarized in Figure 3.4. Receptor activation by E2 
resulted in interaction with a set of nuclear proteins (210) significantly larger 
than those observed with ICI (46), Ral (23), or Tam (49). This result, that 
confirms our previous observations [117, 118], is likely to be due to the 
optimal receptor conformation promoted by the agonist, as well as to 
formation of stable ER homodimers, that provide an efficient docking site for 
interacting proteins. Furthermore, this could be explained, at least in part, by 
the relatively higher concentration of ERα in these samples, which may have 
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facilitated isolation and/or MS identification of interacting proteins. It is 
worth mentioning that the number of molecular partners of ERα in the 
sample treated with E2 for 1 h is comparable to what was previously reported 
for a 2 h stimulation with E2 of the same cells, but the two sets share only 
about 50% of proteins [118], in agreement with the highly dynamic 
ER−protein interactions occurring on BC cell chromatin during the earlier 
phases of hormonal stimulation [128]. 
 
 
 
 
 
 
 
 
 
 
Figure 3.4 Interaction proteomics of agonist- and antagonist-bound ERα in MCF-7 
cells. Venn diagram showing overlaps of interactomes identified following cell treatment 
with E2, Tam, or Ral (10
–8
 M; 1 h). Numbers reported below each symbol indicate the total 
number of specific interactors identified in purified samples by MS. The number within the 
isolated circle at the bottom of the panel indicates interactors specific for ICI treated cells. 
 
The vast majority of the interactors identified are ligand specific and, 
as mentioned above, their number in SERM treated cells is significantly 
lower than that in E2-stimulated cells, with the compositions of the Ral and 
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Tam interactomes being rather different from each other and clearly distinct 
from those of ICI samples. Indeed, comparative analysis of the lists of ERα 
interactors identified with the four compounds tested shows that the majority 
of them are ligand-specific: 200 for E2, 15 for Ral, 36 for Tam, and 21 for 
ICI (Figure 3.4). Interestingly, five proteins not present in the E2 treated 
samples are specific to both SERMs (Table 3.1), suggesting that they might 
represent specific SERM effectors (see also below). It is worth mentioning 
that while the patterns of interactors detected with the two SERMs and E2 are 
very different from each other, the SERD appears to promote recruitment of a 
relatively larger number of proteins in common with E2 (19/ 46), a result that 
could relate to the fact that ICI, unlike SERMs, has a steroid structure like 
that of E2 and could therefore induce a conformational change on the 
receptor that, to some extent, is structurally closer to that elicited by binding 
of the natural hormone. The number of interactors identified does not seem to 
correlate only with concentration of ERα in nuclear extracts or purified 
samples, since, for example, the amount of receptor in Tam samples is only 
slightly lower than that in E2 samples but much higher than that in Ral or ICI 
samples, while the difference in number of binding proteins identified in E2 
vs Tam samples is significant and that in Tam vs Ral or ICI samples is very 
small (compare results in Figure 3.4 with those in Figures 3.1 and 3.6A). On 
the basis of this observation, the known differences in biological activity in 
the BC cells of the compounds tested, and the results reported in Figure 3.3, 
we suggest that the lists of ERα interactors identified in this study, the 
majority of which were not shown before to be partners of the antiestrogen-
bound receptor, represent a snapshot of the early and specific functional 
complexes formed by this protein in BC cell nuclei upon binding to 
antiestrogens, exploitable now to identify the molecular mechanisms that 
determine the variegated pharmacological effects of these drugs in BC cells. 
Functional analysis of the biological processes that involve the ERα 
interacting proteins identified in this study by gene ontology highlights 
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significant differences between agonist (E2)-, SERD-, and SERM-specific 
interactomes (Figure 3.5), that reflect also known effects of these ligands in 
BC cells.  
 
 
Figure 3.5 Gene ontology analysis of the biological processes involving the proteins 
interacting with E2- (red pie chart), ICI- (blue pie chart), Ral- (yellow pie chart), or 
Tam-bound (orange pie chart) ERα. For each treatment a pie chart highlights the most 
significant cellular processes involving the proteins recruited to the receptor by each of the 
ligands studied. 
 
In particular, estrogen promotes recruitment by ER of proteins 
involved in DNA replication and cell cycle progression, chromatin 
remodeling, gene transcription, and RNA splicing and actin cytoskeleton 
organization, while components of the ICI-dependent interactome participate 
in the control of mRNA stability and translation and in regulation of 
apoptosis, all processes associated with the cytostatic actions of this drug. On 
the other hand, the proteins specifically bound to SERM-ER are specifically 
involved not only in regulation of gene expression and signal transduction 
but also in proteolysis, epithelial cell differentiation, cell migration, and 
response to oxidative stress. While most of these functions remain to be 
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elucidated in the context of hormone-responsive BC cells, this result 
confirms the existence of common pathways controlled by estrogen and 
SERMs in this cell type, clearly distinct from those specifically affected by 
ICI. Similar differences between the four lists of interactors were observed 
also when GO term enrichment analysis was performed using as background 
(reference) a list of MCF-7 proteins detected experimentally, obtained by 
combining published results.  
 
 
Table 3.1 Proteins identified specifically in nuclear extracts from SERM-treated cells. 
 
To validate the results obtained by mass spectrometry, WB analysis 
was carried out using a selection of antibodies directed against some of the 
most interesting proteins exhibiting ligand specific association with ERα. 
Among these, we selected the ICI-ERα specific interactor KIAA1967 protein, 
also known as Deleted in breast cancer gene 1, whose expression in MCF-7 
cell nuclei was unaffected by ligand treatment (Figure 3.6A).  
In agreement with the MS results, KIAA1967 was prevalently 
detected by WB in purified TAP−ERα complexes from SERD treated cells 
(Figure 3.6B), despite the low concentration of ERα in these samples. A 
slight amount of this protein in E2 and Tam samples was close to that 
detected in the control sample, despite the very high concentration of receptor 
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under these conditions, confirming a preferential interaction of KIAA1967 
with SERD-bound ERα.  
 
Figure 3.6 Western blot analysis of selected ER nuclear interactors identified by TAP. 
(A) Whole nuclear extracts from wild-type MCF-7 (C) or TAP-ERα cells stimulated with 
E2, ICI, Ral, or Tam (10
–8
 M; 1 h). (B) Validation of MS data. Confirmation of TAP-ERα 
interaction with DOT1L (DOT1-like, histone H3 methyltransferase), KIAA1967 (Deleted 
in breast cancer gene 1/KIAA1967), PDHA1 (pyruvate dehydrogenase (lipoamide) alpha 
1), ACTB (nuclear β-actin), or NPM1 (Nucleophosmin/Nucleolar phosphoprotein 
B23/Numatrin), measured in partially purified samples (bound or eluate TAP fractions). 
Double arrows indicate the presence of two bands detected by the antibodies against human 
PDHA1 and KIAA1967 proteins. 
 
Recruitment of KIAA1967 by ICI liganded ERα may have important 
antitumor effects, as this protein has been shown to be able to interact 
directly with SIRT1 and to inhibit the activity of this enzyme both in vitro 
and in vivo [129]. SIRT1 is involved in cancer cell growth and survival, due 
also to its antiapoptotic activity [130, 131] and ability to silence tumor 
suppressor genes [132]. Interestingly, KIAA1967 has been found over-
expressed in cancer cells [133- 136], suggesting that recruitment of 
KIAA1967 by ICI-liganded ERα may target key cancer genes, resulting in 
their silencing by SIRT1.  
Pyruvate dehydrogenase E1 component subunit α (PDHA1) appears, 
instead, to be a preferred interactor of ERα−Ral and, to a lesser extent, −Tam 
complexes, as confirmed by WB (Figure 3.6). Surprisingly, a significant 
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increase of PDHA1 can be observed in the crude nuclear extracts upon 
treatment of the cells with Ral and, to a lesser extent, with Tam, but not with 
E2 ICI (Figure 3.6A). This appears to be the result of drug-induced nuclear 
translocation of the protein, as the total cellular concentration of PDHA1 did 
not change significantly following treatment (Figure 3.7) and WB analysis of 
the cytoplasm fractions showed reduction of the cytoplasmic concentration of 
PDHA1 in correspondence with its increase in the nuclear compartment (data 
not shown). Pyruvate dehydrogenases, that exert a pivotal role in cellular 
metabolism, were recently assigned an additional function in the nucleus as 
coactivators in STAT5-dependent gene transcription in response to 
interleukin IL-3. This was reported specifically for the pyruvate 
dehydrogenase E2 component (PDHE2), which interacts both in the nucleus 
and in the cytoplasm with the E1 component (PDHE1) [137], suggesting that 
PDHA1 may contribute to the function of PDHE1 as coregulator of SERM− 
ERα complexes for target gene regulation.  
 
 
 
 
 
 
 
Figure 3.7 Western Blot analysis of PDHA1 in whole cell extracts from cells from E2-
, ICI-, Ral- or Tam-stimulated (10
-8
M; 1hr) TAP-ERα cells. C: wt MCF-7 cells stimulated 
with E2, used as negative control. ACTB: β-actin. 
Nuclear levels of β-actin (ACTB) and Nucleophosmin (Nucleolar 
phosphoprotein B23/Numatrin NPM1), two well characterized functional 
partners of estrogen-activated ERα in BC cell nuclei [117], were, instead, not 
affected by treatments (Figure 3.6A), but these proteins were clearly detected 
in E2 stimulated samples (Figure 3.6B), in agreement with the MS results, 
and to a much lower extent, in Tam-treated samples, in agreement with 
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previously published results [117, 118, 138] and with the MS output data, 
that in Tam samples detected peptides from this protein but assigned a low 
MOWSE score. In view of the role that β-actin plays in regulation of gene 
expression, by recruitment of chromatin remodeling complexes and a 
positive effect on RNA polymerase II activity, and the known role of 
Nucleophosmin in ribosome biogenesis, a reduced recruitment of these 
proteins to antiestrogen-bound ERα will result in reduction of receptor effects 
on the above-mentioned processes, which might explain the differences in 
gene regulation shown in Figure 3.3 and the antiestrogenic effects of SERMs 
and SERDs in BC cells both in vitro and in vivo. Interestingly, an additional 
SERM-spcecific interactor, Myosin- IXa, is itself a component of the actin-
based motors involved in intracellular movements and, in particular, in 
collective epithelial cell migration that facilitate formation and maintenance 
of continuous cell layers. In MCF-7 cells, estrogens promote acquisition of 
mesenchymal-like features associated with metastasis development and 
stimulate movement of a subset of estrogen-treated cells as cell clusters 
(collective motility). Antiestrogens, such as Tam, prevent both phenomena. 
[139] Myosin-IXa has been suggested to locally regulate Rho proteins and 
assembly of thin actin bundles associated with nascent cell−cell adhesion, 
which is required to sustain the collective migration of epithelial cells. 
Recruitment of this protein by Ral- and Tam-bound ERα, identified here in 
the nucleus, could also occur in the extranuclear compartment, where it may 
result in reduction of the collective cell migration. Alternatively, binding of 
this protein to SERM-ER could result in accumulation of this protein in the 
nucleus, diverting it from its activities outside this compartment. Another 
interesting SERM-specific ERα interactor discovered here is the DOT1-like, 
histone H3 methyltransferase DOT1L protein, a histone code “writer” lacking 
the SET domain. DOT1L, that is responsible for regulating gene expression 
through histone-methylation (H3K79) [140], can bind to several MLL-fusion 
partners found in acute leukemia and, through this binding, is thought to 
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promote oncogenesis [141, 142]. In order to further investigate DOT1L-ERα 
interaction by an independent experimental approach, 
coimmunoprecipitations were performed. wt MCF-7 cells were stimulated 
with E2, ICI, Ral, or Tam (10
−8
 M, 1 h) or the vehicle alone (V).  
Whole nuclear protein extracts were immunoprecipated with specific 
antibodies against either DOT1L or ERα, and the immunoprecipitates were 
analyzed by Western Blotting with both Abs.  
 
Figure 3.8 DOT1L-ERα coimmunoprecipitation. (A) Immunoprecipition with anti-
DOT1L Abs. Upper panel: whole nuclear extracts from wild-type MCF-7 cells stimulated 
with E2, ICI, Ral, Tam (10
–8
 M; 1 h), or vehicle alone (V); lower panel: 
immunoprecipitates from the same samples. (B) Immunoprecipitation with anti- ERα Abs. 
Upper panel: whole nuclear extracts from wild-type MCF-7 cells stimulated with E2, ICI, 
Ral, Tam (10
–8
 M; 1 h), or vehicle alone (V); lower panel: immunoprecipitates from the 
same samples. 
 
The results shown in Figure 3.8 confirm preferential DOT1L 
interaction not only with SERM- but also with ICI-bound ERα. Interestingly, 
inhibition of DOT1L has been shown to be a valid therapeutic strategy in 
tumor treatment [143]. Recruitment of DOT1L by antiestrogen−ERα 
complexes (Figures 3.6B, 3.8 and Table 3.1) could thus play a role in 
controlling the enzymatic activity of DOT1L and, therefore, modulate its 
downstream targets. 
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Table 3.2  
Proteins specifically identified in partially purified sample upon E2 treatment, including in 
bold, italic and bold italic those in common with Ral, Tam and both SERM ligands, 
respectively. 
 
SwissProt 
ID 
Protein name Gene 
name 
Peptides
matched 
Sequence 
coverage (%) 
MOWSE 
Score 
O00159 Myosin-Ic MYO1C 12 11 254 
O14974 Protein phosphatase 1 
regulatory subunit 12A 
PPP1R12A 3 2 53 
O14979 Heterogeneous nuclear 
ribonucleoprotein D-like 
HNRPDL 4 11 47 
O15020 Spectrin beta chain, brain 
2 
SPTBN2 8 3 29 
O15143 Actin-related protein 2/3 
complex subunit 1B 
ARPC1B 3 11 28 
O15144 Actin-related protein 2/3 
complex subunit 2 
ARPC2 1
 
 4 31 
O15400 Syntaxin-7 STX7 2 5 43 
O15523 ATP-dependent RNA 
helicase DDX3Y 
DDX3Y 6 7 64 
O43143 Putative pre-mRNA-
splicing factor ATP-
dependent RNA helicase 
DHX15 
DHX15 5 2 30 
O43707 Alpha-actinin-4 ACTN4 16 19 482 
O43795 Myosin-Ib MYO1B 30 26 935 
O43866 CD5 antigen-like CD5L 1
 
 2 52 
O60832 H/ACA 
ribonucleoprotein 
complex subunit 4 
DKC1 9 18 244 
O60841 Eukaryotic translation 
initiation factor 5B 
EIF5B 1
 
 0 30 
O75420 PERQ amino acid-rich 
with GYF domain-
containing protein 1 
GIGYF1 5 4 28 
O76021 Ribosomal L1 domain-
containing protein 1 
RSL1D1 11 20 290 
O94906 Pre-mRNA-processing 
factor 6 
PRPF6 8 8 83 
O95782 AP-2 complex subunit 
alpha-1 
AP2A1 9 8 123 
P00367 Glutamate 
dehydrogenase 1, 
mitochondrial 
GLUD1 8 14 274 
P04843 Dolichyl-
diphosphooligosaccharid
e--protein 
glycosyltransferase 
subunit 1 
RPN1 6 10 99 
P05141 ADP/ATP translocase 2 SLC25A5 6 22 326 
P05388 60S acidic ribosomal 
protein P0 
RPLP0 9 40 631 
P06576 ATP synthase subunit 
beta, mitochondrial 
ATP5B 3 6 53 
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P06748 Nucleophosmin NPM1 15 37 563 
P07197 Neurofilament medium 
polypeptide 
NEFM 4 3 31 
P08238 Heat shock protein HSP 
90-beta 
HSP90AB
1 
7 8 29 
P08708 40S ribosomal protein 
S17 
RPS17 3 23 38 
P08754 Guanine nucleotide-
binding protein G(k) 
subunit alpha 
GNAI3 2 7 227 
P0C0S5 Histone H2A.Z H2AFZ 1
 
 7 71 
P11387 DNA topoisomerase 1 TOP1 33 35 1187 
P11388 DNA topoisomerase 2-
alpha 
TOP2A 15 9 381 
P14649 Myosin light chain 6B MYL6B 3 19 115 
P15153 Ras-related C3 
botulinum toxin substrate 
2 
RAC2 2 9 133 
P15880 40S ribosomal protein S2 RPS2 3 10 44 
P15924 Desmoplakin DSP 13 4 29 
P17066 Heat shock 70 kDa 
protein 6 
HSPA6 7 13 245 
P17480 Nucleolar transcription 
factor 1 
UBTF 16 18 226 
P17844 Probable ATP-dependent 
RNA helicase DDX5 
DDX5 27 38 1065 
P18077 60S ribosomal protein 
L35a 
RPL35A 6 38 60 
P18124 60S ribosomal protein L7 RPL7 4 19 215 
P19338 Nucleolin NCL 21 28 1216 
P22087 rRNA 2'-O-
methyltransferase 
fibrillarin 
FBL 5 21 149 
P23246 Splicing factor, proline- 
and glutamine-rich 
SFPQ 18 27 317 
P23396 40S ribosomal protein S3 RPS3 3 11 55 
P26599 Polypyrimidine tract-
binding protein 1 
PTBP1 2 3 44 
P30050 60S ribosomal protein 
L12 
RPL12 5 27 304 
P35249 Replication factor C 
subunit 4 
RFC4 3 9 48 
P35268 60S ribosomal protein 
L22 
RPL22 6 46 435 
P35579 Myosin-9 MYH9 28 15 511 
P35580 Myosin-10 MYH10 7 4 66 
P35659 Protein DEK DEK 8 20 107 
P36578 60S ribosomal protein L4 RPL4 13 28 385 
P36955 Pigment epithelium-
derived factor 
SERPINF1 1
 
 1 32 
P38159 Heterogeneous nuclear 
ribonucleoprotein G 
RBMX 5 15 128 
P39656 Dolichyl-
diphosphooligosaccharid
e--protein 
glycosyltransferase 48 
kDa subunit 
DDOST 1
 
 1 55 
P40429 60S ribosomal protein RPL13A 5 9 42 
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L13a 
P42285 Superkiller viralicidic 
activity 2-like 2 
SKIV2L2 6 5 28 
P46087 Putative ribosomal RNA 
methyltransferase NOP2 
NOP2 6 8 102 
P46776 60S ribosomal protein 
L27a 
RPL27A 4 22 243 
P46777 60S ribosomal protein L5 RPL5 14 40 319 
P46778 60S ribosomal protein 
L21 
RPL21 3 21 37 
P46779 60S ribosomal protein 
L28 
RPL28 12 52 331 
P47756 F-actin-capping protein 
subunit beta 
CAPZB 5 18 123 
P49207 60S ribosomal protein 
L34 
RPL34 4 22 37 
P49916 DNA ligase 3 LIG3 3 2 42 
P50583 Bis(5'-nucleosyl)-
tetraphosphatase 
[asymmetrical] 
NUDT2 1
 
 7 31 
P50914 60S ribosomal protein 
L14 
RPL14 4 20 121 
P51116 Fragile X mental 
retardation syndrome-
related protein 2 
FXR2 3 4 31 
P52272 Heterogeneous nuclear 
ribonucleoprotein M 
HNRNPM 11 15 187 
P52907 F-actin-capping protein 
subunit alpha-1 
CAPZA1 3 15 155 
P53680 AP-2 complex subunit 
sigma 
AP2S1 1
 
 4 40 
P55084 Trifunctional enzyme 
subunit beta 
HADHB 4 7 67 
P60468 Protein transport protein 
Sec61 subunit beta 
SEC61B 2 26 91 
P60866 40S ribosomal protein 
S20 
RPS20 1
 
 5 50 
P61247 40S ribosomal protein 
S3a 
RPS3A 5 18 49 
P61313 60S ribosomal protein 
L15 
RPL15 4 19 139 
P61353 60S ribosomal protein 
L27 
RPL27 3 20 114 
P61513 60S ribosomal protein 
L37a 
RPL37A 2 18 144 
P61803 Dolichyl-
diphosphooligosaccharid
e--protein 
glycosyltransferase 
subunit DAD1 
DAD1 1
 
 8 44 
P62140 Serine/threonine-protein 
phosphatase PP1-beta 
catalytic subunit 
PPP1CB 6 20 87 
P62244 40S ribosomal protein 
S15a 
RPS15A 5 34 102 
P62249 40S ribosomal protein 
S16 
RPS16 4 19 60 
P62266 40S ribosomal protein RPS23 6 30 318 
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S23 
P62269 40S ribosomal protein 
S18 
RPS18 4 24 157 
P62277 40S ribosomal protein 
S13 
RPS13 5 30 51 
P62280 40S ribosomal protein 
S11 
RPS11 6 27 140 
P62424 60S ribosomal protein 
L7a 
RPL7A 3 9 39 
P62701 40S ribosomal protein 
S4, X isoform 
RPS4X 6 19 99 
P62750 60S ribosomal protein 
L23a 
RPL23A 4 13 143 
P62753 40S ribosomal protein S6 RPS6 2 9 102 
P62829 60S ribosomal protein 
L23 
RPL23 4 17 90 
P62841 40S ribosomal protein 
S15 
RPS15 3 13 32 
P62851 40S ribosomal protein 
S25 
RPS25 1
 
 8 61 
P62873 Guanine nucleotide-
binding protein 
G(I)/G(S)/G(T) subunit 
beta-1 
GNB1 6 19 116 
P62879 Guanine nucleotide-
binding protein 
G(I)/G(S)/G(T) subunit 
beta-2 
GNB2 6 19 101 
P62888 60S ribosomal protein 
L30 
RPL30 2 18 123 
P62899 60S ribosomal protein 
L31 
RPL31 6 32 154 
P62913 60S ribosomal protein 
L11 
RPL11 5 23 413 
P62917 60S ribosomal protein L8 RPL8 6 21 259 
P63010 AP-2 complex subunit 
beta 
AP2B1 5 6 59 
P63173 60S ribosomal protein 
L38 
RPL38 1
 
 14 44 
P68032 Actin, alpha cardiac 
muscle 1 
ACTC1 26 34 4608 
P78559 Microtubule-associated 
protein 1A 
MAP1A 4 34 29 
P83111 Serine beta-lactamase-
like protein LACTB, 
mitochondrial 
LACTB 6 11 83 
P83731 60S ribosomal protein 
L24 
RPL24 2 10 30 
P84103 Serine/arginine-rich 
splicing factor 3 
SRSF3 1
 
 5 39 
Q00325 Phosphate carrier 
protein, mitochondrial 
SLC25A3 4 9 64 
Q00577 Transcriptional activator 
protein Pur-alpha 
PURA 2 4 89 
Q01780 Exosome component 10 EXOSC10 8 10 35 
Q01831 DNA repair protein 
complementing XP-C 
cells 
XPC 2 2 46 
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Q02543 60S ribosomal protein 
L18a 
RPL18A 3 14 74 
Q02878 60S ribosomal protein L6 RPL6 6 20 178 
Q02880 DNA topoisomerase 2-
beta 
TOP2B 50 30 1432 
Q03113 Guanine nucleotide-
binding protein subunit 
alpha-12 
GNA12 2 4 227 
Q07020 60S ribosomal protein 
L18 
RPL18 3 18 122 
Q07666 KH domain-containing, 
RNA-binding, signal 
transduction-associated 
protein 1 
KHDRBS1 2 5 72 
Q07955 Serine/arginine-rich 
splicing factor 1 
SRSF1 2 6 43 
Q08945 FACT complex subunit 
SSRP1 
SSRP1 4 5 44 
Q09028 Histone-binding protein 
RBBP4 
RBBP4 3 8 52 
Q12905 Interleukin enhancer-
binding factor 2 
ILF2 4 11 353 
Q13243 Serine/arginine-rich 
splicing factor 5 
SRSF5 3 11 44 
Q13402 Myosin-VIIa MYO7A 8 3 47 
Q14247 Src substrate cortactin CTTN 1
 
 2 30 
Q14344 Guanine nucleotide-
binding protein subunit 
alpha-13 
GNA13 2 6 227 
Q14444 Caprin-1 CAPRIN1 2 1 46 
Q14498 RNA-binding protein 39 RBM39 2 3 27 
Q14789 Golgin subfamily B 
member 1 
GOLGB1 9 3 32 
Q14839 Chromodomain-helicase-
DNA-binding protein 4 
CHD4 9 6 38 
Q14980 Nuclear mitotic 
apparatus protein 1 
NUMA1 11 6 119 
Q15233 Non-POU domain-
containing octamer-
binding protein 
NONO 25 45 561 
Q16643 Drebrin DBN1 2 5 104 
Q16698 2,4-dienoyl-CoA 
reductase, mitochondrial 
DECR1 4 14 102 
Q49A26 Putative oxidoreductase 
GLYR1 
GLYR1 3 5 100 
Q53GS9 U4/U6.U5 tri-snRNP-
associated protein 2 
USP39 3 6 34 
Q5H9F3 BCL-6 corepressor-like 
protein 1 
BCORL1 4 1 38 
Q5JNZ5 Putative 40S ribosomal 
protein S26-like 1 
RPS26P11 3 20 72 
Q5JTH9 RRP12-like protein RRP12 8 5 51 
Q5JWF2 Guanine nucleotide-
binding protein G(s) 
subunit alpha isoforms 
XLas 
GNAS 3 3 288 
Q5SSJ5 Heterochromatin protein 
1-binding protein 3 
HP1BP3 7 12 192 
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Q5T1R4 Transcription factor 
HIVEP3 
HIVEP3 6 2 35 
Q5T280 Uncharacterized protein 
C9orf114 
C9orf114 3 7 37 
Q5TIE3 von Willebrand factor A 
domain-containing 
protein 5B1 
VWA5B1 4 3 34 
Q5VXU9 Uncharacterized protein 
C9orf84 
C9orf84 5 3 27 
Q68E01 Integrator complex 
subunit 3 
INTS3 3 5 36 
Q6PJG2 Uncharacterized protein 
C14orf43 
C14orf43 4 3 55 
Q6UN15 Pre-mRNA 3'-end-
processing factor FIP1 
FIP1L1 2 3 40 
Q6UXE8 Butyrophilin-like protein 
3 
BTNL3 2 4 27 
Q6ZWH5 Serine/threonine-protein 
kinase Nek10 
NEK10 6 6 34 
Q71UM5 40S ribosomal protein 
S27-like 
RPS27L 2 10 56 
Q7RTP6 Protein MICAL-3 MICAL3 9 5 39 
Q7Z406 Myosin-14 MYH14 10 5 265 
Q86UE4 Protein LYRIC MTDH 5 10 67 
Q86V81 THO complex subunit 4 THOC4 2 7 49 
Q8IWU2 Serine/threonine-protein 
kinase LMTK2 
LMTK2 2 1 31 
Q8IY81 Putative rRNA 
methyltransferase 3 
FTSJ3 16 17 351 
Q8IZL8 Proline-, glutamic acid- 
and leucine-rich protein 
1 
PELP1 6 5 103 
Q8N3K9 Cardiomyopathy-
associated protein 5 
CMYA5 13 3 27 
Q8N3X1 Formin-binding protein 4 FNBP4 4 3 28 
Q8N9T8 Protein KRI1 homolog KRI1 2 3 77 
Q8TBZ0 Coiled-coil domain-
containing protein 110 
CCDC110 3  42 
Q8TCU5 Glutamate [NMDA] 
receptor subunit 3A 
GRIN3A 3 2 33 
Q8TDD1 ATP-dependent RNA 
helicase DDX54 
DDX54 10 11 93 
Q8TDI0 Chromodomain-helicase-
DNA-binding protein 5 
CHD5 9 4 38 
Q8TDN6 Ribosome biogenesis 
protein BRX1 homolog 
BRIX1 4 10 60 
Q8WZ42 Titin TTN 52 1 34 
Q92901 60S ribosomal protein 
L3-like 
RPL3L 5 8 243 
Q969L2 Protein MAL2 MAL2 1
 
 63 43 
Q969Q0 60S ribosomal protein 
L36a-like 
RPL36AL 2 14 39 
Q96CW1 AP-2 complex subunit 
mu 
AP2M1 6 13 40 
Q96GQ7 Probable ATP-dependent 
RNA helicase DDX27 
DDX27 12 14 305 
Q96HS1 Serine/threonine-protein 
phosphatase PGAM5, 
PGAM5 6 18 182 
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mitochondrial 
Q96L21 60S ribosomal protein 
L10-like 
RPL10L 1
 
 5 35 
Q96PK6 RNA-binding protein 14 RBM14 6 10 123 
Q99729 Heterogeneous nuclear 
ribonucleoprotein A/B 
HNRNPA
B 
1
 
 2 62 
Q9BQ04 RNA-binding protein 4B RBM4B 4 9 70 
Q9BV38 WD repeat-containing 
protein 18 
WDR18 3 6 66 
Q9BVP2 Guanine nucleotide-
binding protein-like 3 
GNL3 7 12 68 
Q9BX40 Protein LSM14 homolog 
B 
LSM14B 1
 
 3 37 
Q9BXX2 Ankyrin repeat domain-
containing protein 30B 
ANKRD30
B 
5 3 36 
Q9BY44 Eukaryotic translation 
initiation factor 2A 
EIF2A 4 8 35 
Q9H0A0 N-acetyltransferase 10 NAT10 7 7 47 
Q9H0D6 5'-3' exoribonuclease 2 XRN2 6 6 31 
Q9H1H9 Kinesin-like protein 
KIF13A 
KIF13A 8 4 46 
Q9H6R4 Nucleolar protein 6 NOL6 5 4 31 
Q9H6W3 Lysine-specific 
demethylase NO66 
NO66 2 3 54 
Q9HCM4 Band 4.1-like protein 5 EPB41L5 3 4 107 
Q9NPC3 E3 ubiquitin-protein 
ligase CCNB1IP1 
CCNB1IP
1 
2 3 34 
Q9NR30 Nucleolar RNA helicase 
2 
DDX21 3 23 628 
Q9NRC6 Spectrin beta chain, brain 
4 
SPTBN5 15 4 29 
Q9NVI7 ATPase family AAA 
domain-containing 
protein 3A 
ATAD3A 9 12 181 
Q9NW13 RNA-binding protein 28 RBM28 8 10 54 
Q9P2E9 Ribosome-binding 
protein 1 
RRBP1 9 6 166 
Q9UHB6 LIM domain and actin-
binding protein 1 
LIMA1 7 9 51 
Q9ULV4 Coronin-1C CORO1C 5 10 74 
Q9UMS4 Pre-mRNA-processing 
factor 19 
PRPF19 8 17 87 
Q9UPU7 TBC1 domain family 
member 2B 
TBC1D2B 5 5 31 
Q9Y265 RuvB-like 1 RUVBL1 4 10 67 
Q9Y3E5 Peptidyl-tRNA hydrolase 
2, mitochondrial 
PTRH2 1
 
 7 39 
Q9Y3I0 tRNA-splicing ligase 
RtcB homolog 
C22orf28 3 3 39 
Q9Y4P3 Transducin beta-like 
protein 2 
TBL2 1
 
 2 57 
B9A064 Immunoglobulin 
lambda-like 
polypeptide 5 
IGLL5 4 27 449 
P09874 Poly [ADP-ribose] 
polymerase 1 
PARP1 11 14 386 
P09651 Heterogeneous nuclear 
ribonucleoprotein A1 
HNRNPA1 9 19 171 
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P39023 60S ribosomal protein L3 RPL3 12 21 520 
P60709 Actin, cytoplasmic 1 ACTB 35 27 8110 
Q13151 Heterogeneous nuclear 
ribonucleoprotein A0 
HNRNPA0 6 27 151 
Q5QNW6 Histone H2B type 2-F HIST2H2B
F 
2 14 116 
Q6NXT2 Histone H3.3C H3F3C 3 22 50 
Q99459 Cell division cycle 5-like 
protein 
CDC5L 3 3 65 
P03372 Estrogen receptor ESR1 8 14 388 
 46 
Table 3.3  
Proteins specifically identified in partially purified sample upon ICI treatment, including in 
bold, italic and bold italic those in common with E2, SERMs and both E2 and SERMs, 
respectively. 
 
SwissProt 
ID 
Protein name Gene 
name 
Peptides 
matched 
Sequence 
coverage 
(%) 
MOWSE 
Score 
O60812 Heterogeneous nuclear 
ribonucleoprotein C-like 
1 
HNRNP
CL1 
1
 
 3 52 
O75643 U5 small nuclear 
ribonucleoprotein 200 
kDa helicase 
SNRNP2
00 
5 3 28 
P06753 Tropomyosin alpha-3 
chain 
TPM3 5 19 31 
P06850 Corticoliberin CRH 1
 
 3 27 
P08865 40S ribosomal protein 
SA 
RPSA 3 3 47 
P19021 Peptidyl-glycine alpha-
amidating 
monooxygenase 
PAM 1
 
 10 40 
P26196 Probable ATP-dependent 
RNA helicase DDX6 
DDX6 11 27 332 
Q13085 Acetyl-CoA carboxylase 
1 
ACACA 2 0 28 
Q15717 ELAV-like protein 1 ELAVL1 2 7 70 
Q1KMD3 Heterogeneous nuclear 
ribonucleoprotein U-like 
protein 2 
HNRNP
UL2 
7 8 120 
Q5VSP4 Putative lipocalin 1-like 
protein 1 
LCN1P1 2 11 61 
Q6Y7W6 PERQ amino acid-rich 
with GYF domain-
containing protein 2 
GIGYF2 6 5 94 
Q6ZMI0 KLRAQ motif-
containing protein 1 
KLRAQ
1 
5 5 29 
Q8IX12 Cell division cycle and 
apoptosis regulator 
protein 1 
CCAR1 3 2 32 
Q8IYT4 Katanin p60 ATPase-
containing subunit A-like 
2 
KATNA
L2 
3 5 47 
Q8N163 Protein KIAA1967 KIAA19
67 
5 7 70 
Q8N7P1 Inactive phospholipase 
D5 
PLD5 4 7 28 
Q8NAT2 Tudor domain-containing 
protein 5 
TDRD5 3 1 34 
Q8ND56 Protein LSM14 homolog 
A 
LSM14A 13 22 368 
Q92900 Regulator of nonsense 
transcripts 1 
UPF1 3 2 40 
Q9NYF8 Bcl-2-associated 
transcription factor 1 
BCLAF1 2 2 56 
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O43286 Beta-1,4-
galactosyltransferase 5 
B4GAL
T5 
1
 
 1 29 
P11940 Polyadenylate-binding 
protein 1 
PABPC1 7 11 156 
P35637 RNA-binding protein 
FUS 
FUS 6 14 411 
P51991 Heterogeneous nuclear 
ribonucleoprotein A3 
HNRNP
A3 
3 8 48 
P62318 Small nuclear 
ribonucleoprotein Sm 
D3 
SNRPD3 2 14 120 
Q01844 RNA-binding protein 
EWS 
EWSR1 3 4 202 
Q08211 ATP-dependent RNA 
helicase A 
DHX9 9 20 137 
Q12906 Interleukin enhancer-
binding factor 3 
ILF3 4 4 108 
Q6S8J3 POTE ankyrin domain 
family member E 
POTEE 7 17 69 
Q92804 TATA-binding protein-
associated factor 2N 
TAF15 6 11 256 
Q92841 Probable ATP-
dependent RNA 
helicase DDX17 
DDX17 4 6 160 
Q99728 BRCA1-associated 
RING domain protein 1 
BARD1 4 5 36 
Q9BUJ2 Heterogeneous nuclear 
ribonucleoprotein U-
like protein 1 
HNRNP
UL1 
5 6 62 
Q9NTJ4 Alpha-mannosidase 
2C1 
MAN2C
1 
1
 
 0 29 
Q9Y2W1 Thyroid hormone 
receptor-associated 
protein 3 
THRAP
3 
6 6 106 
P02786 Transferrin receptor 
protein 1 
TFRC 7 10 124 
P59665 Neutrophil defensin 1 DEFA1 1
 
 9 50 
P61626 Lysozyme C LYZ 1
 
 8 79 
Q6PJF5 Inactive rhomboid 
protein 2 
RHBDF2 5 4 44 
Q8N957 Ankyrin repeat and 
fibronectin type-III 
domain-containing 
protein 1 
ANKFN1 2 0 29 
Q9NZ71 Regulator of telomere 
elongation helicase 1 
RTEL1 3 2 30 
O60506 Heterogeneous nuclear 
ribonucleoprotein Q 
SYNCRI
P 
4 6 166 
Q7RTV0 PHD finger-like 
domain-containing 
protein 5A 
PHF5A 2 17 50 
Q9H1R3 Myosin light chain 
kinase 2, 
skeletal/cardiac muscle 
MYLK2 2 3 70 
Q9UIB8 SLAM family member 5 CD84 1
 
 2 51 
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Table 3.4  
Proteins specifically identified in partially purified sample upon Ral treatment, including in 
bold, italic and bold italic those respectively in common with E2, Tam and both E2  and 
Tam ligands. 
SwissProt 
ID 
Protein name Gene 
name 
Peptides 
matched 
Sequence 
coverage 
(%) 
MOWSE 
Score 
O15399 Glutamate [NMDA] 
receptor subunit epsilon-4 
GRIN2D 4 2 28 
O75475 PC4 and SFRS1-
interacting protein 
PSIP1 3 4 35 
O95996 Adenomatous polyposis 
coli protein 2 
APC2 5 2 32 
P10276 Retinoic acid receptor 
alpha 
RARA 1
  
 1 30 
P11177 Pyruvate dehydrogenase 
E1 component subunit 
beta, mitochondrial 
PDHB 1
  
 3 30 
P20849 Collagen alpha-1(IX) 
chain 
COL9A1 3 3 28 
P29803 Pyruvate dehydrogenase 
E1 component subunit 
alpha, testis-specific form, 
mitochondrial 
PDHA2  1
  
 2 40 
P51610 Host cell factor 1 HCFC1 3 3 30 
P54253 Ataxin-1 ATXN1 1
  
 1 34 
Q14204 Cytoplasmic dynein 1 
heavy chain 1 
DYNC1
H1 
8 1 32 
Q8NB25 Protein FAM184A FAM184
A 
4 3 32 
Q92851 Caspase-10 CASP10 2 2 37 
Q96RP8 Potassium voltage-gated 
channel subfamily A 
member 7 
KCNA7 1
  
 1 29 
Q9H0C1 Zinc finger MYND 
domain-containing 
protein 12 
ZMYND
12 
1
  
 2 29 
Q9Y6U7 RING finger protein 215 RNF215 2 5 34 
B9A064  Immunoglobulin 
lambda-like polypeptide 
5 
IGLL5 5 30 497 
P09874  Poly [ADP-ribose] 
polymerase 1 
PARP1 1
  
 0 44 
B2RTY4 Myosin-IXa MYO9A 6 2 30 
P08559 Pyruvate dehydrogenase 
E1 component subunit 
alpha, somatic form, 
mitochondrial 
PDHA1 5 11 38 
P12036 Neurofilament heavy 
polypeptide 
NEFH 4 3 93 
Q5VUG0 Scm-like with four MBT 
domains protein 2 
SFMBT2 2 1 30 
Q8TEK3 Histone-lysine N-
methyltransferase, H3 
lysine-79 specific 
DOT1L 5 3 28 
P03372 Estrogen receptor ESR1 4 8 63 
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Table 3.5  
Proteins specifically identified in partially purified sample upon Tam treatment, including 
in bold, italic and bold italic those respectively in common with E2, Ral and both E2 and 
Ral ligands. 
 
SwissProt 
ID 
Protein name Gene 
name 
Peptides 
matched 
Sequence 
coverage 
(%) 
MOWSE 
Score 
A6NMY6  Putative annexin A2-like 
protein 
ANXA2
P2 
1
  
 3 55 
P01833  Polymeric 
immunoglobulin receptor 
PIGR 4 5 124 
P02545  Prelamin-A/C LMNA 2 3 31 
P02787  Serotransferrin TF 4 7 56 
P02788  Lactotransferrin LTF 13 21 321 
P03973  Antileukoproteinase SLPI 2 20 148 
P04406  Glyceraldehyde-3-
phosphate 
dehydrogenase 
GAPDH 2 6 40 
P05089  Arginase-1 ARG1 2 7 30 
P06702  Protein S100-A9 S100A9 6 35 42 
P07339  Cathepsin D CTSD 4 9 35 
P12273  Prolactin-inducible 
protein 
PIP 3 23 112 
P25311  Zinc-alpha-2-
glycoprotein 
AZGP1 2 7 29 
P29508  Serpin B3 SERPIN
B3 
6 11 156 
P31025  Lipocalin-1 LCN1 4 21 176 
P31151  Protein S100-A7 S100A7 2 22 100 
P54652  Heat shock-related 70 
kDa protein 2 
HSPA2 7 13 352 
P62805  Histone H4 HIST1H
4A 
1
  
 7 39 
P78363  Retinal-specific ATP-
binding cassette 
transporter 
ABCA4 2 0 32 
P80188  Neutrophil gelatinase-
associated lipocalin 
LCN2 1
  
 5 43 
Q14103  Heterogeneous nuclear 
ribonucleoprotein D0 
HNRNP
D 
1
  
 2 40 
Q14508  WAP four-disulfide core 
domain protein 2 
WFDC2 1
  
 6 29 
Q16378  Proline-rich protein 4 PRR4 1
  
 11 40 
Q4VXU2  Polyadenylate-binding 
protein 1-like 
PABPC1
L 
2 2 42 
Q5D862  Filaggrin-2 FLG2 3 1 36 
Q5VTT5  Myomesin-3 MYOM3 6 4 28 
Q7Z7A1  Centriolin CEP110 6 3 36 
Q8TDL5  Long palate, lung and 
nasal epithelium 
carcinoma-associated 
protein 1 
LPLUN
C1 
3 6 76 
Q8WUQ7  Uncharacterized protein 
C19orf29 
C19orf29 2 3 33 
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Q92529  SHC-transforming 
protein 3 
SHC3 1
  
 1 29 
Q96DA0  Zymogen granule 
protein 16 homolog B 
ZG16B 1
  
 3 33 
Q96JZ2  Hematopoietic SH2 
domain-containing 
protein 
HSH2D 1
  
 2 32 
Q9BV73  Centrosome-associated 
protein CEP250 
CEP250 9 4 29 
Q9HCF6  Transient receptor 
potential cation channel 
subfamily M member 3 
TRPM3 2 1 30 
Q9UDR5  Alpha-aminoadipic 
semialdehyde synthase, 
mitochondrial 
AASS 3 3 30 
Q9UGM3  Deleted in malignant 
brain tumors 1 protein 
DMBT1 1
  
 0 101 
Q9Y592  Coiled-coil domain-
containing protein 41 
CCDC41 5 5 32 
P60709 Actin, cytoplasmic 1 ACTB 10 22 439 
P09651  Heterogeneous nuclear 
ribonucleoprotein A1 
HNRNP
A1 
3 8 74 
P39023  60S ribosomal protein 
L3 
RPL3 1
  
 2 34 
Q13151  Heterogeneous nuclear 
ribonucleoprotein A0 
HNRNP
A0 
2 8 30 
Q5QNW6  Histone H2B type 2-F HIST2H
2BF 
2 13 31 
Q6NXT2  Histone H3.3C H3F3C 2 15 43 
Q99459  Cell division cycle 5-
like protein 
CDC5L 2 2 27 
B2RTY4  Myosin-IXa MYO9A 6 2 27 
P08559  Pyruvate dehydrogenase 
E1 component subunit 
alpha, somatic form, 
mitochondrial 
PDHA1 1
  
 3 48 
P12036  Neurofilament heavy 
polypeptide 
NEFH 2 1 72 
Q5VUG0  Scm-like with four MBT 
domains protein 2 
SFMBT2 1
  
 1 30 
Q8TEK3  Histone-lysine N-
methyltransferase, H3 
lysine-79 specific 
DOT1L 2 0 27 
P03372 Estrogen receptor ESR1 1
  
 1 40 
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4. CONCLUSIONS 
This study provides for the first time a comparative analysis of the 
effects of antiestrogens on the nuclear ERα interactome of hormone-
responsive human BC cells. The results clearly show that the protein 
complexes recruited by ERα upon estrogen (E2) and antiestrogen (ICI, Ral, 
Tam) stimulation share few components, as the majority of the receptor 
partners identified appear to be ligand-specific. This evidence points to the 
possibility, suggested by a number of indirect observations, that estrogenic 
and antiestrogenic compounds may induce different biological effects in BC 
cells via ERα by promoting recruitment to the receptor of specific molecular 
partners.  
Comparison of the number of interactors shared between two receptor 
complexes to the total number of interactors identified suggests that ERα 
complexes recruited upon SERM stimulation share a relatively higher 
number of common interactors. This result is in agreement with the 
possibility of a direct relationship between the structure of the compound, the 
molecular composition of the interactome, and the biological effects elicited 
by the receptor. 
The known functions of several proteins identified here open new 
venues to investigate the molecular mechanisms underlying SERM inhibition 
of BC cells proliferation and promotion of cell death and to understand the 
events that lead to loss of breast tumor sensitivity to antiestrogen-based 
therapies. 
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5. MATHERIALS AND METHODS  
5.1 Cell cultures  
The human hormone-responsive mammary carcinoma cell line MCF-7 
(Clontech-Takara) was cultured in Dulbecco’s modified Eagle’s medium 
containing 1 mg/mL D-glucose (Sigma-Aldrich) and supplemented with 2 
mM L-glutamine, 10% FBS (HyClone), 25 units/mL penicillin, 25 units/mL 
streptomycin, 250 ng/mL amphotericin B, and 100 μg/mL G418 (standard 
growth conditions). To study protein complexes assembly upon ligand 
treatments, cells were estrogen deprived (starved) by exchanging the medium 
to Dulbecco’s modified Eagle’s medium without phenol red (Sigma-Aldrich) 
supplemented with 2 mM Lglutamine and 5% stripped serum (dextran-coated 
charcoaltreated FBS) 5 days prior to performing the ligand treatments and to 
harvesting the cells, as described by Addeo [144]. MCF-7 cells were used to 
generate stable clones expressing TAP (control cells) or C-TAP-ERα (TAP-
ERα expressing cells) as described by Ambrosino et al.[117]. 
 
5.2 Preparation of nuclear extracts 
The cells were harvested by scraping, washed twice in cold 1× PBS, 
collected by centrifugation at 1000g, and resuspended in 3 volumes with 
respect to the cell pellet of hypotonic buffer (20 mM HEPES pH 7.4, 5 mM 
NaF, 10 mM sodium molybdate, 0.1 mM EDTA, 1 mM PMSF, and 1× 
protease inhibitor mixture (Sigma-Aldrich)). Upon incubation on ice for 15 
min, 0.5% Triton X-100 was added, and a cytosolic fraction was discarded 
after centrifugation of the samples at 15,000g for 30 s at 4 °C. The nuclear 
pellet was first washed twice in hypotonic buffer to remove any residual 
cytosolic contaminations and then was resuspended in 1 volume of nuclear 
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lysis buffer (20 mM HEPES pH 7.4, 25% (v/v) glycerol, 420 mM NaCl, 1.5 
mM MgCl2, 0.2 mM EDTA, 1 mM DTT, 1× protease inhibitor mixture 
(Sigma-Aldrich), and 1 mM PMSF), incubated for 30 min at 4 °C on a 
rotating platform. The nuclear extract was clarified by centrifugation at 
15,000g, for 30 min at 4 °C and then was diluted by adding 2 volumes of 
nuclear lysis buffer w/ o NaCl. The nuclear extracts were assayed, and 
nonsignificant cross-contamination between the two cellular compartments 
could be detected by Western Blotting using an anti-α tubulin antibody [117]. 
 
5.3 Western blotting  
Western blot analyses were performed using standard protocols as 
described by Nassa et al.[145]. In detail, protein samples were denatured, 
separated on a 7 or 10% polyacrylamide and 0.1% SDS (SDS-PAGE), and 
electrotransferred onto a nitrocellulose membrane (Whatman GmbH-
Schleicher & Schuell). The membrane was blocked using 5% (w/v) fat-free 
milk powder in 1× TBS supplemented with 0.1% (v/v) Tween20 (TBS-T). 
The used primary antibodies were as follows: rabbit antihuman ERα (sc-543, 
HC-20, Santa Cruz Biotechnology), rabbit anti- TAP (CAB1001, Thermo 
Scientific-Pierce), rabbit anti-α- tubulin (T6199, Sigma Aldrich), mouse anti-
β-actin (A1978, Sigma Aldrich), rabbit anti-α-tubulin (T6074, Sigma 
Aldrich), mouse anti-DBC1/3G4 (#5857, Cell Signaling), rabbit anti- 
Nucleophosmin (ab52644, Abcam), rabbit anti-DOT1L/ KMT4 (ab72454, 
Abcam), mouse anti-DBC1/3G4 (#5857, Cell Signaling), and mouse anti-
Pyruvate Dehydrogenase E1- alpha subunit (ab110334, Abcam). All 
antibodies were first tested to evaluate specificity and sensitivity. After 
extensively washing with TBS-T, the immunoblotted proteins were incubated 
with the appropriate horseradish peroxidase-conjugated secondary antibodies 
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(GE Healthcare) and were detected by enhanced chemiluminescence (ECL 
Kit, GE Healthcare) and exposure to a medical Xray film (FujiFilm). 
 
5.4 Isolation of ERα nuclear partners by Tandem Affinity Purification  
Control and TAP-ERα expressing cells (approximately 6 × 108 cells in 
500 cm
2
 plates) were used for each tandem affinity purification (TAP) 
procedure. The cells were starved and stimulated with 1 × 10
−8
 M ligand 
(17β-estradiol/E2, 4- hydroxytamoxifen/Tam, Raloxifene/Ral, or 
Fulvestrant/ICI; all from Sigma-Aldrich) for 1 h. Cells were harvested, 
extensively washed with ice-cold 1× PBS, and lysed as described above. 
Nuclear extracts were incubated with 6 μL/mg protein IgG Sepharose beads 
(IgG-Sepharose 6 Fast Flow, GE Helthcare) at 4 °C for 4 h on a rotating 
platform. Before incubation, the beads were equilibrated in 10 volumes of 
TEV buffer (50 mM Tris-HCl, pH 8.0, 0.5 mM EDTA, 1 mM DTT, 0.1% 
Triton X- 100, and 150 mM NaCl), and washed four times with 20 volumes 
of IPP150 buffer (20 mM HEPES, pH 7.5, 8% glycerol, 150 mM NaCl, 0.5 
mM MgCl2, 0.1 mM EDTA, and 0.1% Triton X-100) at 4 °C for 15 min. At 
the end of the incubation, the unbound proteins were collected by 
centrifugation and the beads were washed with 100 volumes of IPP150 and 
30 volumes of TEV buffer in a Poly-Prep Chromatography column (0.8 cm × 
4 cm, Bio-Rad) at 4 °C. Thereafter, 4 bead volumes of TEV buffer containing 
1 unit of TEV protease/μL of beads (Invitrogen) were added and, following 
incubation for 2 h at 16 °C on a shaking platform (Thermomixer, Eppendorf), 
the eluted proteins were collected by sedimentation.  
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5.5 Nano LC-MS/MS analysis of TEV eluates  
The partially purified protein samples from the different experimental 
points were concentrated by precipitation with acetone/TCA, dried, 
sonicated, and resuspended in Laemmli buffer followed by SDS-PAGE and 
visualization with Silver Staining, as described by Nassa et al. [145]. All 
lanes on the gels were excised and were sliced into six pieces, and the 
proteins were in-gel digested with trypsin solution (Sequencing grade 
Modified Trypsin, Promega) and incubated at 37 °C overnight as described 
by [146, 147]. The resulting peptides were acidified and dissolved by 
addition of 0.1% TFA (Sigma-Aldrich) and analyzed by LCMS/ MS using an 
Ultimate 3.000 nano-LC (Dionex, Sunnyvalle, CA, USA) and a QSTAR Elite 
hybrid quadrupole TOF-MS (Applied Biosystems/MDS Sciex, CA, USA) 
with nano-ESI ionization. The LC-MS/MS samples were first loaded on a 
ProteCol C18 trap column (10 mm × 150 μm, 3 μm, 120 Å) (SGE 
Incorporated, Austin, Texas, USA), followed by peptide separation on a 
PepMap100 C18 analytical column (15 cm × 75 μm, 5 μm, 100 Å) (LC 
Packings/Dionex) at 200 nL/min. The separation gradient consisted of 
0−50% B in 50 min, 50% B for 3 min, 50−100% B in 2 min, and 100% B for 
3 min (buffer A: 0.1% formic acid; buffer B: 0.08% formic acid in 80% 
acetonitrile). MS data were acquired using Analyst QS 2.0 software. The 
information-dependent acquisition method consisted of a 0.5 s TOF MS 
survey scan of m/z 400−1400. From every survey scan, the two most 
abundant ions with charge states +2 to +4 were selected for product ion 
scans. Once an ion was selected for MS/MS fragmentation, it was put on an 
exclusion list for 60 s. The LC-MS/MS data were searched against SwissProt 
release 22062011 (529056 sequences; 187423367 residues; Taxonomy Homo 
sapiens (human): 20236 sequences) for all samples using the in-house 
Mascot (version 2.2, Matrix Science) through the ProteinPilot 2.0.1 interface. 
The criteria for Mascot searches were the following: human-specific 
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taxonomy, trypsin digestion with one missed cleavage allowed, and oxidation 
of methionine as a variable modification and carbamidomethylation as a 
fixed modification. For the LC-MS/ MS spectra the maximum precursor ion 
mass tolerance was 50 ppm and the MS/MS fragment ion mass tolerance was 
0.2 Da, and peptide charge states of +1, +2 or +3 were used. All reported 
protein identifications were statistically significant because, instead of a 
Standard Scoring, a MudPIT scoring was used which automatically filters 
low scoring peptide masses. To eliminate the redundancy of proteins that 
appear in the database under different names and accession numbers, the 
single protein member with the highest protein score (top rank) was selected 
from multiprotein families for the identification results. 
 
5.6 Gene Ontology analyses  
Statistically over-represented biological processes were identified 
among the sets of proteins identified by MS analyses in each of the four 
experimental conditions by means of GOFFA [148], a bioinformatics tool for 
the functional analysis of genomic and proteomic data, developed for 
ArrayTrack, that starting from a list of genes or proteins identifies Gene 
Ontology (GO) terms associated with each of them. GOFFA determines the 
statistical significance of a GO term using Fisher’s Exact Test. For this study, 
the list of genes expressed in MCF-7 cells and identified by microarray-
mediated gene expression profiling (see below), was used as a reference and 
for each dataset the GO terms over-represented respect to the reference with a 
p-value ≤ 0.05 were selected. In addition, GO analysis was performed also 
using as a reference a list of proteins identified experimentally in MCF-7 
cells by means of the Gene Ontology Enrichment Analysis and Visualization 
Tool (GORILLA; http://cbl-gorilla.cs.technion.ac.il). 
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5.7 Protein complexes immunoprecipitation  
For immunoprecipitation of endogenous ERα or DOT1L, to nuclear 
extracts from MCF-7 cells (800−2000 μg proteins) was added 2.0−2.5 μg/mg 
protein specific Abs (rabbit antihuman ERα: sc-543, HC-20, Santa Cruz 
Biotechnology and rabbit anti- DOT1L/KMT4: A300-954A, Bethyl), and the 
mixture was incubated for 1−3 h at 4 °C with stirring via rotation; then 
Protein A/G Plus-Agarose was added for 1 h. Immunoprecipitated proteins 
were collected by centrifugation, and after extensive washing, the beads were 
resuspended in Laemmli buffer and subject to SDS-PAGE and Western 
blotting as described by Ambrosino et al [117]. 
 
5.8 RNA purification  
Total RNA was extracted from TAP-ERα expressing cells, using the 
standard RNA extraction with TRI Reagent (Sigma- Aldrich) method, as 
described by Grober at al. [149]. Cells were starved and total RNA was 
extracted after stimulation with 1 × 10
−8
 M ligand (E2, Tam, Ral, or ICI) or 
ethanol vehicle for 12 h. In each case RNA extracted from two independent 
biological replicates was used. Before use, the RNA concentration of each 
sample was assayed with a ND-1000 spectrophotometer (NanoDrop) and its 
quality assessed with the Agilent 2100 Bioanalyzer with an Agilent RNA 
6000 Nano kit (Agilent Technologies). 
 
5.9 RNA expression profiling 
For mRNA expression profiling, 500 ng of total RNA was reverse 
transcribed, as described by Paris et al. [150]and used for synthesis of cDNA 
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and biotinylated cRNA according to the Illumina TotalPrep RNA 
Amplification Kit (Ambion, Cat. no. IL1791) protocol. For each sample, 750 
ng of cRNA was hybridized for 18 h at 58 °C on Illumina Human HT-12v4 
BeadChips (Illumina Inc.), as described by Grober et al. [149] and 
subsequently scanned with the Illumina iScan. Data analyses were performed 
with GenomeStudio software v2011.1 (Illumina Inc.), by comparing all 
values obtained at each time point against the 0 h values. Data were 
normalized with the quantile normalization algorithm, and genes were 
considered as detected if the detection p-value was lower than 0.01. 
Statistical significance was calculated with the Illumina DiffScore, a 
proprietary algorithm that uses the bead standard deviation to build an error 
model. Only genes with a DiffScore ≤−30 and ≥30, corresponding to a p-
value of 0.001, were considered as statistical significant [149, 150]. Raw 
microarray data have been deposited, in a format complying with the 
Minimum Information About a Microarray Gene Experiment (MIAME) 
guidelines of the Microarray Gene Expression Data Society (MGED), in the 
EBI ArrayExpress database (http://www.ebi.ac.uk/arrayexpress) with 
Accession Number E-MTAB-1196. 
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